Chemours Announces Executive Departures and Board Changes
Ticker: CC · Form: 8-K · Filed: Feb 11, 2025 · CIK: 1627223
| Field | Detail |
|---|---|
| Company | Chemours Co (CC) |
| Form Type | 8-K |
| Filed Date | Feb 11, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, board-changes, cfo-departure
Related Tickers: CC
TL;DR
CFO out, new interim CFO and board members in at Chemours.
AI Summary
On February 10, 2025, The Chemours Company announced changes in its executive leadership, including the departure of its Chief Financial Officer, Jonathan F. Seifried. The company also appointed Alisha M. Colvin as Interim Chief Financial Officer and elected new directors to its Board. These changes are effective immediately.
Why It Matters
Significant changes in key executive positions and board composition can signal shifts in company strategy or financial direction, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Executive departures and board changes can introduce uncertainty regarding future strategy and financial management.
Key Players & Entities
- The Chemours Company (company) — Registrant
- Jonathan F. Seifried (person) — Departing Chief Financial Officer
- Alisha M. Colvin (person) — Interim Chief Financial Officer
- Delaware (location) — State of Incorporation
FAQ
Who has been appointed as the Interim Chief Financial Officer?
Alisha M. Colvin has been appointed as the Interim Chief Financial Officer.
When were these changes reported?
These changes were reported on February 11, 2025, with the earliest event reported as February 10, 2025.
What was the previous role of Jonathan F. Seifried?
Jonathan F. Seifried was the Chief Financial Officer of The Chemours Company.
What other significant changes were announced?
The company also announced the election of new directors to its Board.
In which state is The Chemours Company incorporated?
The Chemours Company is incorporated in Delaware.
Filing Stats: 1,006 words · 4 min read · ~3 pages · Grade level 11.5 · Accepted 2025-02-11 16:45:05
Key Financial Figures
- $0.01 — nge on Which Registered Common Stock ($0.01 par value) CC New York Stock Exchan
Filing Documents
- cc-20250210.htm (8-K) — 60KB
- cc-ex99_1.htm (EX-99.1) — 28KB
- img15408389_0.jpg (GRAPHIC) — 72KB
- img173605615_0.jpg (GRAPHIC) — 35KB
- 0000950170-25-017985.txt ( ) — 397KB
- cc-20250210.xsd (EX-101.SCH) — 29KB
- cc-20250210_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On February 10, 2025, the Board approved the Company's 2025 Annual Meeting of Shareholders (the "2025 Annual Meeting") to be held on April 22, 2025 at 10a.m. Eastern time. On February 11, 2025, the Company issued a press release announcing Ms. Turner's appointment to the Board and the date of the Company's 2025 Annual Meeting, which is attached as Exhibit 99.1 hereto.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release, dated as of February 11, 2025 104 Cover Page Interactive Data File (formatted as Inline XBRL). Additional Information and Where to Find It The Company will file with the U.S. Securities and Exchange Commission (the "SEC") a proxy statement with respect to the Company's 2025 Annual Meeting. Shareholders are strongly encouraged to read the proxy statement, when available, and other documents filed with the SEC carefully in their entirety because they will contain important information. Shareholders will be able to obtain any proxy statement, any amendments or supplements thereto and other documents filed by the Company with the SEC free of charge at the SEC's website at www.sec.gov or at the Company's Investors relations website at https://investors.chemours.com/. Certain Information Regarding Participants The Company, its directors and certain of its executive officers will be participants in the solicitation of proxies from the Company's shareholders in connection with the matters to be considered at the 2025 Annual Meeting. Information about the Company's directors and executive officers is available in the Company's annual report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on March 27, 2024, and the proxy statement filed with the SEC on April 11, 2024 with respect to the Company's 2024 Annual Meeting of Shareholders. To the extent holdings of the Company's securities by such directors or executive officers have changed since the amounts printed in the proxy statement with respect to the Company's 2024 Annual Meeting of Shareholders, such changes have been or will be reflected on Statements of Changes in Beneficial Ownership on Form 4 filed with the SEC. Additional information regarding the participants and their direct or indirect securities holdings will be set forth in the proxy statement and other materials to be filed with the SEC in connec
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. THE CHEMOURS COMPANY By: /s/ Shane Hostetter Shane Hostetter Senior Vice President, Chief Financial Officer Date: February 11, 2025